泰林生物(300813.SZ):擬變更部分首發募集資金用途 用於細胞治療產業化裝備製造基地項目
格隆匯 1 月 8日丨泰林生物(300813.SZ)公佈,根據市場變化及公司經營需要,為提高募集資金使用效率,公司擬終止“研發中心項目”和“銷售網絡及技術服務建設項目”,並將上述兩個項目的募集資金餘額5985.22萬元(包含累計收到的銀行利息收入及理財收益並扣除手續費等,因該事項經董事會審議通過至經股東大會審議後具體實施時存在一定時間間隔,具體金額以實施時實際剩餘募集資金金額為準)調整用於新項目“細胞治療產業化裝備製造基地項目”。
此次擬變更募集資金投資項目金額(不包含累計收到的銀行利息收入及理財收益並扣除手續費等)佔公司首次公開發行募集資金淨額的比例為29.27%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.